证券代码：600085 证券简称：同仁堂 公告编号：2025-006 北京同仁堂股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：每股派发现金红利 0.50 元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将 在权益分派实施公告中明确。 在实施权益分派的股权登记日前，北京同仁堂股份有限公司（以下简称公司） 的总股本如发生变动的，拟维持分配总额不变，相应调整每股分配比例，并将另 行公告具体调整情况。 公司未触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以下简称 《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示 的情形。 一、利润分配预案内容 (一) 利润分配方案的具体内容 经中审众环会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 公司合并报表期末未分配利润为人民币 8,386,175,950.07 元，母公司报表中期末 未分配利润为人民币 3,804 ...

北京同仁堂股份有限公司2024 年年度报告 公司代码：600085 公司简称：同仁堂 北京同仁堂股份有限公司 2024 年年度报告 1 / 239 北京同仁堂股份有限公司2024 年年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、中审众环会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人 邸淑兵、主管会计工作负责人 温凯婷 及会计机构负责人（会计主管人员）王 燕声明：保证年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经中审众环会计师事务所（特殊普通合伙）审计，2024 年度本公司按照合并报表实现归属于 母公司股东的净利润 1,526,274,925.98 元，按母公司实现净利润的 10%提取法定盈余公积 139,331,446.76 元，加年初未分配利润 8,370,702,732.85 元，减去 2023 年度及 2024 年半年度利润 分配已向全体 ...

核心品种再聚焦，推广资源再聚集。当北京同仁堂科技发展股份有限公司（以下简称"同仁堂科技"）大 品种战略实施五年之际，企业在品种建设上又迈出坚实一步，将资源分配给更"能打"的核心品种。在当 下宏观经济环境复杂变化，市场竞争日益白热化的当下，同仁堂科技这一举措无疑传递出更强烈的"提 质增效"信号。 在非药产品板块，同仁堂科技将继续深挖非药类品种的市场潜力，特别是阿胶食品系列、枇杷露、清脂 茶等大健康产品以及香类等文创产品，用好现有的销售渠道宽度和品种宽度，加大线上线下渠道开发， 在新品研发、品牌联合、产品共建、渠道专销、跨界合作上实现新的突破。 （文章来源：证券日报） 2025年，同仁堂科技继续深化"大品种战略"，凭借大品种"头羊"效应，实现以优势品种带动潜力品种， 全面构建营销矩阵，打造明星产品核心驱动、多元品种协同的组合模式。 据了解，同仁堂科技已筛选出京制牛黄解毒片、西黄丸、六味地黄丸、感冒清热颗粒、加味逍遥丸5个 核心大单品，制定差异化营销策略，将核心单品做优做强，进一步扩大核心单品的市场份额。 极富同仁堂特色的"御药300年"系列品种培育也是重要环节，同仁堂科技相关负责人表示，"御药300 年"系列产品 ...

而同仁堂科技深受合作伙伴欢迎，频频打开市场与渠道空白点的"插旗行动"也将在今年推出升级版，活 动将以"成熟市场巩固，空白市场不白"为原则，以京制牛黄解毒片、西黄丸、感冒清热颗粒、六味地黄 丸、加味逍遥丸等核心品种为突破口，进一步拓宽活动的深度和广度，向消费者传递产品信息、健康知 识等，提升品牌形象，促进产品销售。 "营销模式的调整要跟得上市场的变化。"同仁堂科技相关负责人表示，企业将进一步推动营销模式向着 更灵敏的方向转型，以高效的"扁平化"配置为出发点，缩短销售链条，提高流通效率，同时持续优化各 品种的控销效果，加强对产品、价格、渠道、终端和市场的全面掌控，逐步搭建更为良性立体的品种发 展生态，充分释放品牌优势和市场潜力。 为了达到提升"渠道盈利能力"这一目标，同仁堂科技在年初已对战略合作伙伴、终端渠道、电商渠道等 资源进行深度整合，根据不同区域、不同品类、不同渠道精准施策，给予营销资源倾斜。 以终端门店为例，企业发力打造单体旗舰店，出台标准化的管理流程，规范品种经营数量、活动开展、 产品码放等方面要求，并为旗舰门店提供定制促销品、路演活动、落地广告投放等全方位终端支持。据 了解，合作粘性高的旗舰店还将嵌入 ...

3月28日，同仁堂国药披露2024年业绩公告，报告期内，同仁堂国药实现收入16.12亿港元，同比增长 5.7%；实现净利润5.29亿港元。 强化研发创新成果加速转化落地 2024年，同仁堂国药不断强化产品生产及研发，精益管理，加速形成新质生产力，不断向价值链高端攀 升，成果丰硕。报告期内，同仁堂国药推出同仁堂仙龄、保龄中式抗衰老NMN系列产品、灵芝姜黄复 方活血安神胶囊、桂枝茯苓丸、活络油等新产品，积极扩大自有产品矩阵。 此外，在科技创新方面，当归补血颗粒通过审批获得中成药注册证，进一步丰富了同仁堂国药品种资 源。 北京同仁堂国药有限公司（以下简称"同仁堂国药"，股票代码：3613.HK）是同仁堂集团的海外发展平 台，经营中药产品的生产、零售及批发业务。 2004年成立至今，同仁堂始终坚持"以医带药，文化先行"的方式，深入践行"责任担当创造"的新时代同 仁堂精神，将传承精华、守正创新融入生产经营的每一个环节，不断培育新质生产力传播中医智慧和中 医健康养生理念，为实现"有健康需求的地方就有同仁堂"的宏伟目标贡献着力量。 2024年，同仁堂国药积极应对外部环境变化，不断优化内部管理，多维度开展营销活动，确保公司平 ...

Group 1 - The core viewpoint of the article emphasizes the potential investment opportunities in Tong Ren Tang Guo Yao, driven by its solid financial performance and growth prospects in the traditional Chinese medicine sector [1][2][3] - The company reported a revenue of HKD 1,611.6 million for 2024, a 5.7% increase from HKD 1,524.9 million in 2023, with significant growth in the Hong Kong market [3][4] - The compound annual growth rate (CAGR) for revenue since its listing in 2013 is 8.38%, while net profit CAGR is 7.27%, indicating a stable growth trajectory [4] Group 2 - The company maintains a low debt ratio of 2.9% and has a strong cash flow, with cash and cash equivalents amounting to HKD 18.20 billion in 2024 [5] - The gross profit margin has averaged around 69% over the past five years, supported by key products like An Gong Niu Huang Wan and Lingzhi, which contribute significantly to cash accumulation [4][5] - The dividend payout ratio for 2024 reached 58.6%, reflecting the company's commitment to returning value to shareholders [5] Group 3 - The traditional Chinese medicine industry is expected to experience accelerated growth due to increasing recognition of Chinese medicine culture and supportive government policies [6] - The market for traditional Chinese medicine in China is projected to exceed CNY 1 trillion in 2023, driven by an aging population and rising health awareness [6] Group 4 - An Gong Niu Huang Wan, a core product of the company, has a strong brand presence and is recognized for its unique therapeutic properties, contributing to a solid competitive advantage [7][8] - The company is expanding its overseas market presence, with over 160 retail outlets established across various regions, including Asia, Oceania, North America, and Europe [12] Group 5 - The company is actively pursuing product registration in international markets, enhancing its global footprint and tapping into the growing demand for traditional Chinese medicine [13][14] - Recent collaborations with academic institutions aim to modernize traditional Chinese medicine and facilitate its acceptance in Western markets [14] Group 6 - The company is focusing on product innovation, launching new products such as anti-aging series and herbal formulations, which are expected to enhance its product portfolio [15][16] - The company is also strengthening its online sales channels, partnering with major e-commerce platforms to expand its market reach [17] Group 7 - The Hong Kong pharmaceutical sector is undergoing a revaluation, with Tong Ren Tang Guo Yao positioned as a strong candidate for investment due to its growth potential and historical low valuation [18][19] - The company is anticipated to benefit from a "Davis Double Play," where both valuation and performance are expected to improve simultaneously [20]

Group 1 - The core viewpoint of the news is that Tongrentang Technology has made significant progress in its traditional Chinese medicine processing project in Yutian, Hebei, with over 50 sets of equipment successfully installed and operational work underway [1][2][3] Group 2 - In 2024, coinciding with the 10th anniversary of the Beijing-Tianjin-Hebei coordinated development strategy, Tongrentang Technology has initiated the construction of a traditional Chinese medicine processing workshop to enhance its processing capacity and optimize its industrial layout [2] - The project is located in the National Agricultural Science and Technology Park in Yutian County, Tangshan City, covering an area of 80 acres, primarily focusing on the preparation of raw medicinal materials [2] - The first phase of the project includes three main buildings: Factory 1, Pre-treatment Workshop 2, and Raw Material Storage 3, along with eight auxiliary buildings [2] Group 3 - Since the project's launch, multiple construction milestones have been successfully achieved, with all three main buildings completed and finishing touches on decoration and renovation underway [3] - The successful installation of production equipment marks a critical milestone, bringing the project closer to completion and production [3] - Once phase one is completed, the production base will have the capacity to produce 4 million kilograms of processed medicinal materials annually, enhancing the company's processing capabilities and supply capacity [3]

Core Viewpoint - Tongrentang Technology reported a revenue of 7.26 billion and a net profit of 0.887 billion for the fiscal year 2024, demonstrating resilience in a challenging pharmaceutical market environment [1] Group 1: Financial Performance - The company achieved a revenue of 7.26 billion and a net profit of 0.887 billion during the reporting period [1] - Despite challenges such as rising raw material prices and decreased foot traffic in stores, the company improved its overall operational quality [1] Group 2: Innovation and R&D - Tongrentang Technology increased its investment in research and development, accelerating the development of innovative drugs and classic formulas [2] - The company received clinical trial approval for Qishen Granules, marking its first clinical approval for a traditional Chinese medicine in eight years [2] - Several products underwent pharmacological mechanism studies, enhancing their market competitiveness and clinical recognition [2] Group 3: Market Strategy and Product Expansion - In response to external challenges, the company adjusted its market strategy, focusing on channel management, price stability, and terminal empowerment [3] - The company launched promotional activities for its "Yuyao 300" product line, resulting in nine products exceeding 0.1 billion in sales [3] Group 4: Channel Development - Tongrentang Technology strengthened its partnerships with major distributors and conducted over 450 promotional events in previously untapped markets [4] - The company aimed to enhance product distribution rates and terminal effectiveness through targeted market strategies [4] Group 5: Risk Management and Future Plans - The company plans to enhance its governance and core competitiveness to address risks and challenges [5] - Future initiatives include a new round of collaborative innovation in traditional Chinese medicine, aiming to complete clinical research on five products by 2025 [5]

Core Viewpoint - The traditional Chinese medicine (TCM) industry is at a new historical starting point, presenting new development opportunities for companies like Tong Ren Tang [1] Financial Performance - In 2024, Tong Ren Tang achieved revenue of HKD 1,611.6 million, a 5.7% increase from HKD 1,524.9 million in 2023, with a net profit of HKD 529.2 million [3] - The final dividend per share increased to HKD 0.35 from HKD 0.33 in 2023 [3] - The Hong Kong market contributed over 50% to the company's total revenue, with a 16.9% year-on-year growth in revenue to HKD 1,069.7 million [3] Operational Strategy - The company expanded its retail presence in Hong Kong by adding two new retail outlets, enhancing market coverage [3] - Tong Ren Tang maintains a stable gross profit margin and had a debt ratio of 2.9% with cash and cash equivalents of approximately HKD 1.82 billion [4] - The company has a history of active dividend policies, with cumulative dividends reaching HKD 3 billion, reflecting strong cash flow and profitability [4] Product Development and Innovation - Tong Ren Tang is focusing on product innovation and research, launching several new products in 2024, including anti-aging and herbal formulations [5] - The company has received multiple patents for its products, enhancing its competitive edge [6][7] International Expansion - The company is actively expanding its international presence, with a sales network covering major regions including Asia, Oceania, North America, and Europe [8] - Tong Ren Tang is registering key products in Southeast Asian countries and has established a presence in New Zealand, becoming the largest TCM chain in the region [8][9] Brand and Market Positioning - The company emphasizes balancing commercial and social value, engaging in community health initiatives and promoting TCM culture [10] - Tong Ren Tang has strengthened its brand influence through advertising and participation in global trade events, receiving multiple awards for its brand recognition [11][12] Industry Outlook - The TCM industry is benefiting from favorable policies and increasing public interest in health, positioning it as a promising sector in the pharmaceutical field [13] - The company aims to enhance retail efficiency, diversify its product matrix, and invest in core projects to capture more market share [13]

Core Viewpoint - The Chinese medicine industry is poised for high-quality development driven by government policies, with Tong Ren Tang Technology (01666.HK) positioned to benefit from this trend through its comprehensive capabilities and strategic alignment with policy directions [1][5]. Financial Performance - In 2024, Tong Ren Tang Technology achieved revenue of 7.26 billion RMB, a year-on-year increase of 7.18%, and a net profit of 888 million RMB, with a return to shareholders of 0.18 RMB per share [2]. - Despite facing cost pressures, the company maintained stable revenue performance, leveraging its full industry chain advantages and refined management to control procurement costs [2][3]. - The company reported 56 products with sales exceeding 5 million RMB, including 9 products with sales over 100 million RMB, indicating robust growth in core products [3]. Market Opportunities - The government’s support for traditional Chinese medicine and consumption policies creates favorable conditions for market expansion of core products like An Gong Niu Huang Wan and Gan Mao Qing Re Granules [6]. - The adjustment of the medical insurance catalog in 2024 is expected to favor innovative Chinese medicine products, potentially leading to revenue recovery for the company [6]. Competitive Strengths - Tong Ren Tang Technology's competitive edge lies in its full industry chain, covering everything from raw material cultivation to terminal services, ensuring stable supply and quality [7]. - The company is actively promoting product innovation and has received approval for its innovative drug Qi Shen Granules, which is set to enter clinical trials [8]. - The company has been recognized for its research achievements, winning the 2024 Beijing Science and Technology Progress Award, showcasing its strong R&D capabilities [8]. Cost Dynamics - The company has faced pressure from rising raw material costs, but a recent decline in Chinese medicinal material prices is expected to improve profitability [10]. - The overall cost pressure on downstream Chinese medicine companies is anticipated to decrease, allowing for improved margins [10]. Long-term Growth Potential - The company is positioned for value growth through policy-driven short-term performance recovery, industry chain advantages, and international market expansion [11]. - With a dynamic P/E ratio of approximately 9 times, the company is expected to maintain a valuation premium due to its brand value and market competitiveness [11].